Resources from the same session
860MO - Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC)
Presenter: Hye Ryun Kim
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
861MO - Spatial distribution of CD8+ and FoxP3+ in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (HNSCC)
Presenter: Joseph Curry
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
862MO - Gene expression profile differentiates short-term and long-term survivors with immunotherapy in patients with recurrent/metastatic head and neck cancer
Presenter: Loris De Cecco
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
863MO - Nomogram for predicting survival for patients receiving definitive chemoradiation in locally advanced squamous cell carcinoma of the head and neck: A secondary analysis of NRG/RTOG 0129, 0522, and 1016
Presenter: Michael Kharouta
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
864MO - Role of geriatric assessment in tailoring treatment of locally advanced head and neck cancer: The ELDERLY study
Presenter: Paolo Bossi
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
865MO - RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation
Presenter: Nandini Menon
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Abstract
Slides
Webcast
Discussion 860MO, 861MO and 862MO
Presenter: Sara Pai
Session: Mini oral session - Head and neck cancer, excl. thyroid
Resources:
Slides
Webcast